Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

NCT05753384 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Tyrosine Kinase Inhibitors
Chronic Myeloid Leukemia

Interventions

DRUG: treatment of TKI in CML

Sponsor

Poitiers University Hospital